Kjell G Stenberg

Cyxone accelerates development pace

Biotechnology company Cyxone entered 2020 strengthened when both of the company's drug candidates, T20K and Rabeximod, achieved important clinical milestones last...

Cyxone's CEO on animal testing - will be extra careful in the future

Many have surely been touched by the disgusting images...

Warrant gives Cyxone cash injection

Since mid-2019, Cyxone's share price has risen by...

Cyxone aims for orphan drug status

Biotechnology company Cyxone will evaluate whether it is possible to...

Halfway through 2019, Cyxone has two candidates in clinical development

For the biotechnology company Cyxone, the past six months have...

Cyxone applies for phase IIb clinical trial with Rabeximod

The Swedish biotechnology company

BioStock's article series on autoimmune disease: Drug Development for RA and MS

Therapies for autoimmune diseases are available but do...

Cyxone begins first-in-human study with T20K following Dutch regulatory approval

With the approval received from the relevant...

International MS Day: Cyxone aims for better and safer treatments for MS patients

While traditional MS treatments are receiving strong criticism from...

Cyxone wants to position T20K in a prophylactic treatment for MS

Biotechnology company Cyxone recently announced that preclinical results...

CEO Cyxone: »I am disappointed with the disciplinary committee's decision«

Biotechnology company Cyxone announced today that the disciplinary committee at Nasdaq...

Watch the interviews with Aptahem, Sobi & Cyxone from BioStock Live

In connection with Wednesday's BioStock Live, the companies'...